ETBX-011
- Generic Name
- ETBX-011
- Drug Type
- Biotech
- Unique Ingredient Identifier
- RP9RQ0SOM8
- Background
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Phase 2
Withdrawn
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.088: NANT Pancreatic Cancer Vaccine
Phase 2
Withdrawn
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Phase 1
Terminated
- Conditions
- mCRCColorectal Cancer Metastatic
- Interventions
- Procedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
Phase 2
Withdrawn
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03554109
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Urothelial Carcinoma
- Interventions
- Drug: 5Fluorouracil (5-FU)Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
Phase 1
Withdrawn
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03175666
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169764
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
Phase 1
Withdrawn
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169777
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath